The ZOLL Foundation

Early-stage research funding


About the Foundation

The ZOLL® Foundation supports early-stage research that is focused on improving care for patients suffering from serious cardiopulmonary and respiratory conditions.

By providing "seed" grants for young researchers around the world, the ZOLL Foundation promotes investigation into science and medical technologies with the potential to enhance patient care. Funding is aimed at research in several areas, including resuscitation and acute critical care, cardiac monitoring, circulation enhancement, temperature management, ventilation, and the connection between sleep apnea and cardiac disease.

Applications for funding are reviewed by the ZOLL Foundation’s Board of Directors twice a year, with deadlines of March 31 and September 30. Grant approvals are oriented toward:

  • early research in new therapies or techniques;
  • reviews of data and information to better understand training and treatment practices;
  • educational activities combined with measurement to enhance care; and
  • promising start-up projects whose initial results may allow researchers to seek additional funding from other sources, enabling continued research that will require more extensive trials or scale.

Since its inception, the ZOLL Foundation has awarded more than $5 million in research grants to 118 recipients.

Established in 2013 by ZOLL® Medical Corporation, the ZOLL Foundation is a nonprofit organization that qualifies as tax-exempt under the United States Internal Revenue Code Section 501(c)(3). Contributions to the ZOLL Foundation from organizations and individuals are tax-deductible under Section 170 of the Code. The ZOLL Foundation is also registered as a non–profit charity with the Office of the Attorney General for the Commonwealth of Massachusetts.

Paul M. Zoll, MD

ZOLL Medical, co-founded by Paul M. Zoll, MD in 1980, provides medical devices, software and related services that are used worldwide to diagnose and treat patients suffering from serious cardiopulmonary and respiratory conditions. Dr. Zoll’s seminal work in electrophysiology — including internal and external defibrillation, cardioversion, external pacing, and mechanical CPR devices — provided the foundation for ZOLL to become the world’s leading company in medical technologies for resuscitation. Today, Dr. Zoll’s emphasis on innovation, curiosity and perseverance live on in ZOLL Medical’s dedication to improving patient outcomes, advancing emergency care and helping save lives, and increasing clinical and operational efficiencies